[Role of leukotriene inhibitors in the treatment of childhood asthma].
Leukotriene inhibitors are new pharmacological agents for the treatment of mild to moderate persistent asthma and exercise-induced asthma (EIA). Studies concerning their use in children remain scarce. Available data in the treatment of persistent asthma in children suggest that they could be an alternative to long-acting beta 2-agonists when asthma control cannot be obtained with inhaled steroids alone. Their main advantages are first that they are given orally once daily; second, that they do not induce tachyphylaxis to bronchoprotection against EIA, unlike long-acting beta 2-agonists. Studies specifically conducted in children are necessary to best describe their place in pediatric asthma treatment.
Romanet
S
S
Service de pneumologie-allergologie, hôpital Sainte-Marguerite, Marseille, France.
Stremler-Lebel
N
N
Magnan
A
A
Dubus
J C
JC
D000284:Administration, Oral; D001249:Asthma / Q000188:drug therapy*; D002648:Child; D004334:Drug Administration Schedule; D006801:Humans; D020024:Leukotriene Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D010372:Pediatrics
D020024:Leukotriene Antagonists